Xero Limited (ASX: XRO)
Xero Limited (ASX: XRO) reported strong financial results for H1 FY25, with operating revenue growing by 25% to reach $995.9 million. This growth was driven by a combination of higher Average Revenue Per User (ARPU) and increased subscriber numbers. The company's Annualised Monthly Recurring Revenue (AMRR) grew 22% to $2.2 billion, and total Lifetime Value (LTV) increased by 15% to $17.0 billion. Xero also successfully removed 160,000 long-idle subscriptions, which had minimal impact on overall revenue, while adding 186,000 new subscribers in the period.
The company introduced new subscription plans in key markets like Australia, the UK, and New Zealand to simplify customer experiences and meet evolving needs. In addition to these changes, Xero’s product and feature development ramped up, with highlights including the launch of Tap to Pay in the Xero Accounting mobile app, increased direct bank feeds in North America, and the release of the GenAI-powered "Just Ask Xero" (JAX) companion. Other advancements include new payroll solutions and improved UK tax offerings.
Besides organic growth, Xero is accelerating its strategic initiatives through acquisitions and partnerships. It announced plans to acquire Sy Analytics to enhance its analytics and reporting capabilities and extended its partnership with Gusto to provide a seamless embedded payroll solution for US customers. These moves are aligned with the company's strategic focus on enhancing customer solutions and streamlining operations in its three largest markets. Xero's operating expenses for FY25 are expected to be around 73% of revenue, with product development costs remaining similar to FY24 levels.
CSL Limited (ASX: CSL)
CSL Limited (ASX: CSL) is focused on sustainable growth, with an emphasis on addressing unmet medical needs, particularly in the areas of immunoglobulin (Ig), plasma therapies, and vaccines. They are actively working to enhance their research and development pipeline, focusing on new therapies for diseases like Hemophilia B through their gene therapy, HEMGENIX. Despite some setbacks, such as halting certain clinical trials, CSL continues to invest heavily in innovation. Their strategic acquisition of Vifor Pharma has contributed to long-term growth potential, even though there have been unexpected challenges in the near term. Progress has been made with key initiatives, such as the rollout of advanced plasmapheresis devices, an increase in CSL Plasma app downloads, and ongoing efforts to improve yield efficiency. These are expected to drive profitable growth while delivering value to shareholders.
CSL’s financial outlook for FY25 is strong, with a projected revenue growth of 5-7% at constant currency and a 10-13% increase in NPATA. In CSL Behring, demand for Ig remains robust, with initiatives like Rika and I-Nomogram improving efficiency. The company is also preparing for the regulatory outcomes and potential launch of Garadacimab. In CSL Seqirus, continued success is expected from their differentiated vaccine portfolio, with further expansion of the sa-mRNA COVID vaccine and the preparation of submissions for the EU and US. Meanwhile, CSL Vifor remains focused on iron competition and nephrology growth, while also advancing collaborations with CSL Behring in patient blood management. With these initiatives in place, CSL aims to maintain its leadership position in the healthcare market and deliver long-term growth and value.
Source: Company’s Report
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.
